tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Spyre Therapeutics Announces Public Stock Offering
PremiumCompany AnnouncementsSpyre Therapeutics Announces Public Stock Offering
14d ago
Spyre Therapeutics 14.86M share Spot Secondary priced at $18.50
Premium
The Fly
Spyre Therapeutics 14.86M share Spot Secondary priced at $18.50
16d ago
Spyre Therapeutics announces common stock offering, no amount given
Premium
The Fly
Spyre Therapeutics announces common stock offering, no amount given
16d ago
Strategic Growth and Innovation Drive Buy Rating for Spyre Therapeutics
PremiumRatingsStrategic Growth and Innovation Drive Buy Rating for Spyre Therapeutics
2M ago
Buy Rating for Spyre Therapeutics: Promising AFFINITY Study Results in Autoimmune Disease Market
Premium
Ratings
Buy Rating for Spyre Therapeutics: Promising AFFINITY Study Results in Autoimmune Disease Market
2M ago
Promising Potential of Spyre Therapeutics’ Innovative IBD Treatments Earns Buy Rating
Premium
Ratings
Promising Potential of Spyre Therapeutics’ Innovative IBD Treatments Earns Buy Rating
2M ago
Spyre Therapeutics: Strategic Execution and Promising Clinical Data Justify Buy Rating
PremiumRatingsSpyre Therapeutics: Strategic Execution and Promising Clinical Data Justify Buy Rating
4M ago
Promising Potential and Strategic Growth Justify Buy Rating for Spyre Therapeutics
Premium
Ratings
Promising Potential and Strategic Growth Justify Buy Rating for Spyre Therapeutics
4M ago
Buy Rating for Spyre Therapeutics: Promising Monoclonal Antibodies and Strategic Market Positioning
Premium
Ratings
Buy Rating for Spyre Therapeutics: Promising Monoclonal Antibodies and Strategic Market Positioning
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100